Can Novartis really make its medicines available to everyone?

Writing for Swissinfo, Jessica Davis Plüss asks whether Switzerland-based Novartis's "experiment" to make its products widely available will succeed, citing the company's ranking in the 2021 Access to Medicine Index.

Jessica discusses the shift in the company's focus on reaching the low- and middle-income countries through the so-called "emerging market brands", with asthma and migraine treatments as notable examples. She also refers to the company's response to the current pandemic.

The article further highlights the need for transparency across the pharmaceutical industry over the pricing and R&D costs of the health products, noting that transparency will truly lead to sustainable and broad access to medicine for more patients.

Read the full article here.